Two doses of mRNA vaccine elicit cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant

• Published in: bioRxiv
• Main Authors: Kotaki, Ryutaro, Adachi, Yu, Moriyama, Saya, Onodera, Taishi, Fukushi, Shuetsu, Nagakura, Takaki, Tonouchi, Keisuke, Terahara, Kazutaka, Sun, Lin, Takano, Tomohiro, Nishiyama, Ayae, Shinkai, Masaharu, Oba, Kunihiro, Nakamura-Uchiyama, Fukumi, Shimizu, Hidefumi, Suzuki, Tadaki, Matsumura, Takayuki, Isogawa, Masanori, Takahashi, Yoshimasa
• Format: Paper
• Language: Japanese
• Published: Cold Spring Harbor Laboratory 26.12.2021
• Edition: 1.1
• Subjects: Immunology
• ISSN: 2692-8205
• DOI: 10.1101/2021.12.24.474091

SARS-CoV-2 Beta and Omicron variants have multiple mutations in the receptor-binding domain (RBD) allowing antibody evasion. Despite the resistance to circulating antibodies in those who received two doses of mRNA vaccine, the third dose prominently recalls cross-neutralizing antibodies with expanded breadth to these variants. Herein, we longitudinally profiled the cellular composition of persistent memory B-cell subsets and their antibody reactivity against these variants following the second vaccine dose. The vaccination elicited a memory B-cell subset with resting phenotype that dominated the other subsets at 4.9 months. Notably, most of the resting memory subset retained the ability to bind the Beta variant, and the memory-derived antibodies cross-neutralized the Beta and Omicron variants at frequencies of 59% and 29%, respectively. The preservation of cross-neutralizing antibody repertoires in the durable memory B-cell subset likely contributes to the prominent recall of cross-neutralizing antibodies following the third dose of the vaccine. Fully vaccinated individuals preserve cross-neutralizing memory B-cells against the SARS-CoV-2 Omicron variant.